Study of NT219 in combination with gemcitabine for the treatment of advanced pancreatic cancer

Trial Profile

Study of NT219 in combination with gemcitabine for the treatment of advanced pancreatic cancer

Planning
Phase of Trial: Phase I/II

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs NT 219 (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 01 Nov 2017 According to a Kitov Pharmaceuticals media release, an IND submission is expected in the first half of 2019.
    • 16 Aug 2017 According to a Kitov Pharmaceuticals media release, the company expects to initiate the clinical trial in 2018.
    • 17 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top